Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease

摘要

Use of a selective cytokine inhibitory drug selected from cyclopropyl-N-{2[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, which has the structure (I) as shown herein, and pharmaceutically acceptable salts and solvates thereof, in the preparation of a composition for treating Behcet's disease is disclosed.